Folate, Homocysteine, and Adverse Outcomes After Ischemic Stroke
Open Access
- 1 October 2024
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (19) , e036527
Abstract
Background: As a risk factor of cardiovascular diseases, homocysteine can be effectively lowered by folate. However, the associations of folate and homocysteine levels with the prognosis of ischemic stroke remained unclear. Methods and Results: A total of 3530 patients with ischemic stroke were included. Serum folate and homocysteine levels were measured at admission. The primary outcome was composite of death and major disability (modified Rankin Scale score≥3) at 3 months after stroke onset. Univariate and multivariate logistic regression models were used. The mediation effect of homocysteine was examined. During follow‐up, 1056 participants developed the primary outcome. In the univariate model, participants in the highest quartile of folate had a 29% (95% CI, 0.58–0.87) decreased risk of primary outcome compared with those in the lowest quartile. After multivariate adjustment, the odds ratio associated with the highest quartile of folate was 0.58 (95% CI, 0.46–0.73) for primary outcome. In contrast, participants in the highest quartile of homocysteine had a 52% (95% CI, 1.24–1.98) increased risk of primary outcome compared with those in the lowest quartile. After multivariate adjustment, the odds ratio associated with highest quartile of homocysteine was 1.57 (95% CI, 1.24–1.98) for primary outcome. In addition, 25.5% of the observed associations between folate and primary outcome was mediated through homocysteine ( P =0.012). Conclusions: High folate levels were associated with low risks of death and major disability among Chinese patients with ischemic stroke, and homocysteine partially mediated the observed potential beneficial role of folate.Keywords
This publication has 35 references indexed in Scilit:
- Global heterogeneity in folic acid fortification policies and implications for prevention of neural tube defects and stroke: a systematic revieweClinicalMedicine, 2023
- Temporal trend and attributable risk factors of stroke burden in China, 1990–2019: an analysis for the Global Burden of Disease Study 2019The Lancet Public Health, 2021
- Homocysteine-lowering interventions for preventing cardiovascular eventsCochrane Database of Systematic Reviews, 2017
- One-Carbon Metabolism in Health and DiseaseCell Metabolism, 2017
- B vitamins in patients with recent transient ischaemic attack or stroke in the VITAmins TO Prevent Stroke (VITATOPS) trial: a randomised, double-blind, parallel, placebo-controlled trialThe Lancet Neurology, 2010
- Lowering Homocysteine in Patients With Ischemic Stroke to Prevent Recurrent Stroke, Myocardial Infarction, and DeathJAMA, 2004
- Homocysteine and Risk of Ischemic Heart Disease and StrokeJAMA, 2002
- Folic acid and homocysteine in age-related diseaseAgeing Research Reviews, 2002
- Mediation in experimental and nonexperimental studies: New procedures and recommendations.Psychological Methods, 2002
- Flexible regression models with cubic splinesStatistics in Medicine, 1989